BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tacere Therapeutics Appoints Vice President, Research And Development


11/14/2006 12:29:13 PM

SAN JOSE, Calif., Nov. 14 /PRNewswire/ -- Tacere Therapeutics, Inc., an innovative biotechnology company specializing in the development of RNAi therapeutics to treat serious infectious diseases, announced today that Linda B. Couto, Ph.D., has joined as Vice President, Research and Development.

Prior to Tacere, Dr. Couto was the Senior Director of Preclinical Biology at Benitec Ltd. Previously she held a number of positions at Avigen, Inc., ultimately as Senior Director of Applied Research. At Avigen, she conducted research on AAV gene transfer to treat a number of inherited diseases. Dr. Couto was responsible for the preclinical translational research that led to the successful filing of two investigational new drug applications (INDs) for hemophilia B. From 1990-1995, she was a research scientist at Somatix working in the area of ex vivo gene therapy. She has published numerous articles and book chapters, including several on the development of RNAi therapeutics for infectious disease. She holds a Ph.D. in molecular toxicology from MIT.

Sara M. Hall, President and Chief Executive Officer of Tacere, commented, "We are pleased that Linda has joined our team, as she was one of the key developers of our lead clinical candidate for the treatment of Hepatitis C, TT-033i. Her experience in RNAi therapeutic development and gene medicine in general allows us to advance TT-033i to clinical trials quickly and fully informed by the past. RNAi has advanced as a therapeutic modality so quickly, from proof of concept to Phase 2 clinical trials in less than four years, that it is critical for us to remain at the forefront through scientific leadership. As there are few in the field with the knowledge and experience of Linda, it is to our advantage that she has chosen to continue to work with us on this potential cure for Hepatitis C."

Tacere was founded by Sara M. Hall; Mike Catelani, Chairman, SVP & CFO of Tacere; Dr. John Monahan, founder and former CEO of Avigen, Inc.; and Dr. Amit Kumar, CEO of CombiMatrix Corporation. Scientific advisors of Tacere include notable scientists and clinicians Dr. Paul Pockros, Director of the Liver Disease Center and Scripps Clinic Research Consortium; Dr. Robert Lanford, Scientist at the Southwest Foundation for Biomedical Research and the Southwest National Primate Research Center; and Dr. Jonathan Coates, Founder and Chief Scientific Officer of Avexa Ltd.

About Tacere Therapeutics, Inc.

Tacere is an innovative biotechnology company focused on developing therapeutics to treat serious infectious diseases using its proprietary knowledge in the screening and development of both novel and traditional compounds. Tacere is located in San Jose, California, USA. Its lead therapeutic compound is TT-033i, an RNA interference (RNAi) drug for the treatment of Hepatitis C. For additional information, please visit www.tacerebio.com.

CONTACTS: TACERE THERAPEUTICS, INC. Mike Catelani, Chairman, SVP & CFO +1 (408) 960-2205 mcatelani@tacerebio.com MEDIA CONTACT: Gregory Tiberend Richard Lewis Communications, Inc. +1 (212) 827-0020 gtiberend@rlcinc.com

Tacere Therapeutics, Inc.

CONTACT: Mike Catelani, Chairman, SVP & CFO, of Tacere Therapeutics, Inc.,+1-408-960-2205, or mcatelani@tacerebio.com; or Gregory Tiberend of RichardLewis Communications, Inc., +1-212-827-0020, or gtiberend@rlcinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES